brain neoplasms/tyrosine

Веза се чува у привремену меморију

Изаберите тип сортирања

Страна 1 од 22 резултати

18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The management and prognosis of patients with glioma is highly dependent on the tumour grade according to the new 2016 classification of the World Health Organization (WHO), which incorporates molecular characteristics. Standard magnetic resonance imaging (MRI) enhanced by contrast is the basis of

FBY PET/CT in Patients With Brain Tumors

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

FBY is a new PET tracer derived from tyrosine, with the carboxyl group replaced by boron trifluoride, and is transferred across cell membrane through LAT-1. LAT-1 is a sodium independent amino acid transporter and is highly expressed in tumor cells. Considering the significant role in cancer

Sunitinib in Sarcomas of the Central Nervous System

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background: - Gliosarcoma and primary CNS sarcomas are malignant brain tumors uniformly associated with poor outcome. - There are no known effective medical therapies for these cancers. - Sunitinib is an orally administered small molecule that inhibits signaling of multiple receptor tyrosine kinases

FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND: - Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract, and traditional cytotoxic chemotherapy is not effective. Patients with Neurofibromatosis 1 (NF1) have an increased risk of developing GIST, and surgery remains the only standard

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background: - Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered and penetrates blood brain barrier (BBB). There is clinical experience in using

Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Gliomas account for almost 80% of primary malignant brain tumors, and glioblastoma is the most common subtype. Despite treatment with surgery, radiation, and chemotherapy(Temozolomide) almost all patients with glioma experience recurrence and the median survival for most patients is less than 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Glioblastoma multiforme (GBM), the most common primary brain tumor in adults is known for its highly invasive and angiogenic profile. Despite advances in different modalities of GBM treatment, the overall prognosis of GBM remains dismal. The current standard of care is Radiation Therapy (RT) at a

Using Genomic Analysis to Guide Individual Treatment in Glioblastoma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The purpose of the study is to assess whether the use of genomics can identify patient specific treatment choices in glioblastoma (GBM) that improves clinical outcomes over standard of care. GBM is a devastating disease, the most common primary brain tumor and the most aggressive. With current

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background - Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventions, significant numbers of pediatric cancer

Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Brain metastases are a common and serious complication of metastatic melanoma. Up to 50% of patients develop brain metastases during the course of their illness, and approximately 20% of patients have them at first presentation with metastatic disease. The prognosis for melanoma patients

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Glioblastoma (GBM), the most common and most malignant primary brain tumor, represents a major medical challenge considering its extremely poor prognosis (Wen 2008). Current standard of care includes maximal surgical resection, followed by concomitant radio-chemotherapy (temozolomide - TMZ) (RT-CT)

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Despite intensive treatment efforts combining surgery, radio- and chemotherapy, the prognosis of patients suffering from glioblastoma (GBM) remains poor. Virtually all GBMs progress despite therapy. Patients receiving the standard therapy at primary disease have a median overall survival of 12-15

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background - Glioblastoma (GBM) is the most common primary brain tumor. With optimal treatment,consisting of focal radiotherapy with concurrent chemotherapy, followed by adjuvant chemotherapy, median survival is 14.6 months. Most patients have evidence of tumor progression within one year of

Претходна
1
2
Следећи

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима